Entrada Therapeutics Inc (TRDA) Directors and Executive Officers

Officers & Directors

Kush M. Parmar, M.D., Ph.D. - Chairman and Director

Mary Thistle - Director

Kory Wentworth - Chief Financial Officer

Dipal Doshi - Chief Executive Officer and Director

Bernhardt Zeiher, M.D. - Director

Gina Chapman - Director

Peter S. Kim, Ph.D. - Director,

Entrada Therapeutics Inc currently has 152 employees.

News about Entrada Therapeutics Inc Key Personnel

Entrada Therapeutics Launches ELEVATE-45-201 Study, Pioneering Exon Skipping Strategies in Duchenne Muscular Dystrophy Treatment

In a significant advancement for the treatment of Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics has received authorization from the United Kingdom s regulatory authorities to initiate the ELEVATE-45-201 study. This Phase 1/2 Multiple Ascending Dose clinical trial will assess ENTR-601-45, a promising investigational drug designed for individuals living with DMD who are amenable to exon 45 skipping. This authorization comes at a time of heightened urgency to discover effective therapeutic strategies for a condition that has long stymied conventional treatments.DMD is a devastating genetic disorder primarily affecting young males and characterized by relentless muscle degeneration and weakness. The un...